Lumida
/AHCO
⌘K
Adapthealth Corp

Adapthealth Corp

AHCO
$6.06USD+3.59%+0.21 today

MARKET CAP

826.2M

P/E (TTM)

FWD P/E

DAY RANGE

$6 – $6

52W RANGE

$5
$13

AI Summary

Stalk
StalkMedium

AHCO remains in a bullish medium-term structure with successive higher highs and higher lows, supported by rising EMAs and strong up-day volume. Price is approaching resistance and is extended above key moving averages, suggesting patience is required. We will stalk for a pullback into the $10.50–$10.80 confluence zone for a higher-odds buy, as EMAs remain supportive and RSI holds above mid-range.

  • Q2 revenue rose 12.7% YoY to $740.3M with 15.9% organic growth.
  • Divested $235M diabetes unit to improve margin profile.
  • Adjusted EBITDA guidance lowered to $490–520M amid cost pressures.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$2.5B$3.0B$3.2B$3.3B$3.2B
YoY %+130.2%+20.5%+7.7%+1.9%-0.5%
P / Sales1.3x0.9x0.3x0.4x0.4x
EV / Sales2.6x1.9x1.2x1.3x1.2x
Gross Profit, Adj.$456.2M$580.1M$624.1M$681.1M$609.2M
YoY %+165.1%+27.2%+7.6%+9.1%-10.6%
Margin %18.5%19.5%19.5%20.9%18.8%
EV / Gross Profit13.8x9.8x6.3x6.0x6.6x
EBITDA, Adj.$512.3M$541.6M$615.2M$642.1M$568.2M
YoY %+233.1%+5.7%+13.6%+4.4%-11.5%
Margin %20.8%18.2%19.2%19.7%17.5%
EV / EBITDA12.3x10.5x6.4x6.4x7.1x
EBIT$225.6M$190.4M$-598.4M$263.7M$58.3M
YoY %+216.2%-15.6%-414.3%+144.1%-77.9%
Margin %9.2%6.4%-18.7%8.1%1.8%
EV / EBIT27.9x30.0x-6.6x15.5x69.2x
Net Income$141.8M$63.4M$-678.9M$82.7M$-70.8M
YoY %+187.7%-55.3%-1170.0%+112.2%-185.6%
Net Margin5.8%2.1%-21.2%2.5%-2.2%
EPS (GAAP)$0.67$0.33-$5.31$0.61-$0.52
YoY %+121.8%-50.7%-1709.1%+111.5%-185.2%